Clinical trial
Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
NCT00185588 · George Albert Fisher, Other · Completed
Key facts
| NCT number | NCT00185588 |
|---|---|
| Title | Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer |
| Official title | A Phase 1-2 Study of the VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 <Vatalanib> and Gemcitabine in Patients With Advanced Pancreatic Cancer |
| Lead sponsor | George Albert Fisher, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Vatalanib, Gemcitabine |
| Enrollment | 33 |
| Start date | Oct 1, 2004 |
| Primary completion | Jan 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Sep 16, 2005 |
| Last update posted | Sep 15, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: